ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
miR-218 suppressed the growth of lung carcinoma by reducing MEF2D expression.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Functional significance of miR-218 in lung cancer.Journal of cancer metastasis and treatment · 2026Article
- Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.Biology · 2022Article
- Effects and mechanism of microRNA‑218 against lung cancer.Molecular medicine reports · 2021Article
- MEF2D sustains activation of effector Foxp3+ Tregs during transplant survival and anticancer immunity.The Journal of clinical investigation · 2020Article
- MiR-125b-2-3p associates with prognosis of ccRCC through promoting tumor metastasis via targeting EGR1.American journal of translational research · 2020Article
- Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes.Journal of experimental & clinical cancer research : CR · 2019Article
- Yarrow supercritical extract exerts antitumoral properties by targeting lipid metabolism in pancreatic cancer.PloS one · 2019Article
- miR-218 suppresses the proliferation of osteosarcoma through downregulation of E2F2.Oncology letters · 2019Article
- NAIF1 suppresses osteosarcoma progression and is regulated by miR-128.Cell biochemistry and function · 2018Article
- The Long Noncoding RNA D63785 Regulates Chemotherapy Sensitivity in Human Gastric Cancer by Targeting miR-422a.Molecular therapy. Nucleic acids · 2018Article
- Absent expression of miR-30a promotes the growth of lung cancer cells by targeting MEF2D.Oncology letters · 2018Article
- miR-30a suppresses osteosarcoma proliferation and metastasis by downregulating MEF2D expression.OncoTargets and therapy · 2018Article
- miR-136 targets MIEN1 and involves the metastasis of colon cancer by suppressing epithelial-to-mesenchymal transition.OncoTargets and therapy · 2018Article
- Downregulation of miR-30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer.Oncology letters · 2017Article
- MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value.Oncotarget · 2017Article
- Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer.Journal of translational medicine · 2017Article
- Article
- MEF2D/Wnt/β-catenin pathway regulates the proliferation of gastric cancer cells and is regulated by microRNA-19.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.Oncology reports · 2016Article
- Let-7a gene knockdown protects against cerebral ischemia/reperfusion injury.Neural regeneration research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung carcinoma is a deadly malignant disease with poor prognosis and increasing incidence in recent years. However, the molecular mechanism underlying the initiation and progression of lung cancer is still not completely elucidated. Recently, myocyte enhancer factor 2D (MEF2D) has been reported to promote the growth of liver cancer, but its implication in lung cancer is still unknown. This study is aimed to determine the role of MEF2D in lung carcinoma. Quantitative PCR (qPCR) and immunoblot assays showed that MEF2D was overexpressed in lung cancer tissues and cell lines, compared with the matched normal tissues and cell lines. Small interfering RNA (siRNA) suppression of MEF2D was able to reduce the proliferation, survival, and invasion of lung carcinoma cells. The transfection of MEF2D-expressing constructs into normal lung fibroblast cells promoted their proliferation and motility. The role of MEF2D in the growth of lung cancer was also confirmed in mice. Further study revealed that miR-218, which was underexpressed in lung carcinoma, was predicted to bind the 3'-untranslated region (UTR) of MEF2D mRNA. miR-218 was shown to suppress the activity of luciferase with MEF2D 3'-UTR. The changes in miR-218 levels affected the expression of MEF2D in lung cancer cells and normal fibroblast cells. There is also an inverse association between miR-218 abundance and MEF2D levels in the lung carcinoma specimen. Furthermore, the transfection of a plasmid that expressed MEF2D resistance to miR-218 regulation abolished the inhibitory effect of miR-218 on lung cancer cells. Collectively, MEF2D overexpression participated in the growth of lung cancers and its aberrant expression may result from the reduction of tumor suppressor miR-218.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.